FOLH1 and prostate carcinoma: Molecular imaging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has emerged as one of the leading diagnostic procedures to investigate prostate cancer (PCa) patients, due to its high diagnostic accuracy in detecting disease localizations in biochemically recurrent PCa [1,2,3,4,5,6,7,8,9], as well as its promising results in the setting of primary staging [10,11,12,13,14].